Expanding the potential of radiopharmaceuticals
Aktis Oncology’s proprietary miniprotein radioconjugate is helping to transform the treatment landscape by enabling the discovery of next-generation precision radiopharmaceuticals.
Opportunity for impact
Our platform has the transformational potential to increase addressable tumor types, enable use of radiopharmaceuticals in earlier lines of therapy, and expand utilization of radiopharmaceuticals in the clinical oncology setting.
We see significant opportunity to broaden the cancer patient populations benefiting from targeted radiopharmaceuticals by developing next-generation technologies that expand the scope of clinically validated tumor targets for which it is possible to safely deliver a powerful payload of an alpha-emitting radioisotope.
Expanding the breakthrough potential of targeted radiopharmaceuticals
The power to see and know
A key component of our approach is the ability to leverage imaging tools to understand precisely where our radiopharmaceuticals are being delivered in the body. By employing a theranostic approach, we can visualize and verify tumor target engagement, allowing us to better predict which patients are most likely to benefit from this type of therapy.
Scaling for the future
Carefully timed and coordinated logistics are critical for effective delivery of radiopharmaceuticals whose activity diminish over time. Aktis Oncology is engaged at every step of the manufacturing process to ensure just-in-time delivery of its radiopharmaceuticals. We prioritize the physician and patient experience to ease the traditional limitations of radiopharmaceuticals and to ensure our medicines make it to the patients who need them.
Get in touch
Reach out to learn more about how Aktis Oncology is revolutionizing radiopharmaceuticals.
